Methyl Prednisolonate

ApprovedSmall molecule

Methyl Prednisolonate is one of 128 small molecule programs targeting Hypersensitivity Pneumonitis. It is currently in Approved.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypersensitivity PneumonitisActive, not recruiting

Shoulder PainActive, not recruiting

PneumoniaActive, not recruiting

Multiple SclerosisActive, not recruiting

Heart DiseaseActive, not recruiting

Hypersensitivity PneumonitisApproved

Active, not recruiting

Shoulder PainPhase 1

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

Multiple SclerosisPreclinical

Active, not recruiting

Heart DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Methyl Prednisolonate

UUniversity Hospital Muenster

Approved

1 2

Betaseron

Bayer

Preclinical

16 3

Tysabri

Biogen

Preclinical

14 4

Avonex

EMD Serono

Preclinical

22 5

Campath

GGenzyme, a Sanofi Company

Preclinical

12 6

Zinbryta

Roche

Preclinical

2 7

Flomax

Sanofi

Preclinical

1 8

Pred Forte

Myfortic

Lunesta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Disease1 trial

High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease

Unknown status·—·Phase 4·NCT05103397·75 enrolled

Multiple Sclerosis1 trial

Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis

Unknown status·UUniversity Hospital Muenster··NCT04450030·204 enrolled

Shoulder pain1 trial

Ultrasound Guided Botulinum Toxin Type A Injection of Subacromial-Subdeltoid Bursa in Hemiplegic Shoulder Pain

Unknown status·—·Phase 1·NCT04467450·36 enrolled

Pneumonia1 trial

Low Versus High Corticosteroid Use in Ventilator Associated Pneumonia

Completed·KKing Abdul Aziz Specialist Hospital·Phase 2·NCT04467892·240 enrolled

Hypersensitivity Pneumonitis1 trial

This Study Aim is to Compare the Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis as it Was Found That Not All Patients Get Satisfying Therapeutic Effect After Taking Corticosteroids.

Unknown status·—·Phase 4·NCT04402177·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Methyl Prednisolonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methyl Prednisolonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methyl Prednisolonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Muenster company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital Muenster

Methyl Prednisolonate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Disease1 trial

Multiple Sclerosis1 trial

Shoulder pain1 trial

Pneumonia1 trial

Hypersensitivity Pneumonitis1 trial

References

Drug Info

Quick Facts

Related News